The HVTN 124 clinical trial is wrapping up while the stability of the used vaccines is confirmed.
HVTN 124 is a phase 1 clinical trial conducted by NIH-funded HIV Vaccine Trials Network, testing the safety and immunogenicity of PDPHV-201401, WHV’s preventive HIV vaccine candidate. The trial has now been formally concluded with the lock of the database. Volunteers and researchers will be unblinded to the treatment group assignment in the near future. The preliminary data from the peak immunogenicity analyses are very encouraging and support the advancement of this vaccine candidate to further clinical testing. The data will be presented at the HVTN’s annual 2021 Full Group Meeting on May 5-7, 2021.
Working with Waisman Biomanufacturing, WHV also formally completed the studies initiated by Dr. Shan Lu’s laboratory at UMass as part of the IPCAVD program to test the stability of all vaccine components used in the HVTN 124 trial. The results of these studies indicate that DNA vaccine, gp120 Env recombinant protein vaccine, and the GLA-SE adjuvant are all stable after 4-5 years and can be used in the planned WHV 138 clinical trial. To support the use of these vaccines in the WHV 138 trial, WHV extended the stability studies for all components.
